High prevalence of cannabis use among patients with hidradenitis suppurativa: results from the VERADDICT survey.

Dear Editor, Garg et al.[1] recently highlighted that cannabis use was more common in patients with hidradenitis suppurativa (HS) (1-2%) compared with the general population (0-4%). Interestingly, in the HS group, a more elevated visual analogue scale (VAS) pain score during remission was statistically associated with cannabis use (1-7/10 vs. 1-1/10, P = 0-03), whereas the VAS pain score during flares was no different among cannabis users and nonusers. Overall, in our study more than one in three patients with HS were cannabis users and of these almost 40% were daily users, with an elevated risk of cannabis-related adverse effects such as early arteritis. [Extracted from the article]